Clinical trial
Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer
NCT00712140 · Warwick Medical School, Other · Unknown status
Key facts
| NCT number | NCT00712140 |
|---|---|
| Title | Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer |
| Official title | Persephone: Duration of Trastuzumab With Chemotherapy in Women With Early Stage Breast Cancer: Six Months Versus Twelve |
| Lead sponsor | Warwick Medical School, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, parenteral chemotherapy |
| Enrollment | 4,000 |
| Start date | Oct 1, 2007 |
| Primary completion | Oct 1, 2011 |
| First posted | Jul 9, 2008 |
| Last update posted | Sep 2, 2011 |
| Countries | United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: